Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17709177 | 0.85 | KDM4E (0.43) | GABRA1 | |
| SCHEMBL17708851 | 0.83 | CYP19A1 (0.63) | CFTRCYP19A1CYP3A4MAOBMEN1 | |
| Hydrochloric Acid SCHEMBL17709050 | 0.83 | CYP19A1 (0.44) | CYP19A1CYP3A4MAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL17709078 | 0.82 | CYP19A1 (0.48) | CYP19A1CYP3A4MAOBCA1CA2 | |
| Hydrochloric Acid SCHEMBL17709161 | 0.82 | CYP19A1 (0.62) | CFTRCYP19A1CYP3A4MAOBMEN1 | |
| SCHEMBL17708853 | 0.79 | CFTR (0.46) | CFTRGABRA1TMEM97SIGMAR1CYP19A1 | |
| Hydrochloric Acid SCHEMBL17709108 | 0.78 | CFTR (0.45) | CFTRGABRA1TMEM97SIGMAR1CYP19A1 | |
| SCHEMBL17708808 | 0.78 | CFTR (0.55) | CFTRCYP19A1MAOBMEN1KMT2A | |
| SCHEMBL17708958 | 0.77 | CYP19A1 (0.53) | CYP19A1CYP3A4MAOBMEN1KMT2A | |
| SCHEMBL19469601 | 0.77 | CFTR (0.48) | CFTRGABRA1TMEM97SIGMAR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107405337-B | Substituted chromans and methods of use | 艾伯维公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| WO-2017187321-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | AbbVie S.à.r.l. (LU) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
| EP-3212189-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | AbbVie S.À.R.L. (LU) | 2017-09-06 | — | — | EP | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| WO-2016069757-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CFTR 1/4885GABRA1 3122/4885TMEM97 972/4885 |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | CFTR 1/4885GABRA1 2211/4885TMEM97 192/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | CFTR 1/4885GABRA1 2211/4885TMEM97 192/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CFTR 1/4885GABRA1 3122/4885TMEM97 972/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | CFTR 1/4885GABRA1 3122/4885TMEM97 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.